The Life Sciences team advised Corsera Health, Inc. on raising $80 million in a Series A financing. Forbion and Population Health Partners co-led the oversubscribed Series A which included participation from other leading investors, including Corsera Co-Founder and Co-CEO John Maraganore, Ph.D. In connection with the Series A financing, Marco Boorsma, Ph.D., General Partner at Forbion, will join the board of directors of Corsera Health.
The proceeds will fund the company’s approach to extending healthspan by empowering individuals to understand and reduce their risk of atherosclerotic cardiovascular disease (ASCVD). The funding will also support continued development of Klotho, Corsera Health’s proprietary AI-enabled precision health platform, which is designed to predict lifetime cardiovascular disease risk and quantify the potential benefit of lowering LDL-C and blood pressure to extend cardiovascular healthspan.
Corsera Health aims to lead the future of medicine by extending healthspan through cardiovascular disease prediction and prevention. Co-founded by industry pioneers in RNAi therapeutics and cardiovascular medicine, the company is combining decades of innovation in RNAi therapeutics with world-leading expertise in cardiovascular disease prediction, efficient manufacturing and evidence generation, and disruptive commercialization. Corsera Health is headquartered in Boston, Mass.
The Goodwin deal team was led by Samuel Beavers, Richard Matheny, Kingsley Taft, Ryan Donahoe, Gözde Güçkaya, and Angela Kim.
For more information on the deal, please read the press release and coverage in Endpoints News.